A5017734916- CAR-T cell therapy research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Biomedical Ethics and Regulation
- Monoclonal and Polyclonal Antibodies Research
- Biosimilars and Bioanalytical Methods
- Manufacturing Process and Optimization
- HIV Research and Treatment
- Cancer Research and Treatments
- HIV/AIDS drug development and treatment
- Cancer Cells and Metastasis
- Bacterial biofilms and quorum sensing
- bioluminescence and chemiluminescence research
University Medical Center Utrecht
2018-2024
Utrecht University
2019-2024
Center for Translational Molecular Medicine
2021
Atma Jaya Catholic University of Indonesia
2021
University of Amsterdam
2016
Amsterdam UMC Location University of Amsterdam
2016
Extending the success of cellular immunotherapies against blood cancers to realm solid tumors will require improved in vitro models that reveal therapeutic modes action at molecular level. Here we describe a system, called BEHAV3D, developed study dynamic interactions immune cells and patient cancer organoids by means imaging transcriptomics. We apply BEHAV3D live-track >150,000 engineered T cultured with patient-derived, solid-tumor organoids, identifying 'super engager' behavioral cluster...
<h3>Background</h3> γ9δ2T cells, which express Vγ9 and Vδ2 chains of the T cell receptor (TCR), mediate cancer immune surveillance by sensing early metabolic changes in malignant leukemic blast not their healthy hematopoietic stem counterparts via γ9δ2TCR targeting joined conformational spatial CD277 at membrane (CD277J). This concept led to development next generation CAR-T so-called TEGs: αβT cells Engineered a defined γδTCR. The high affinity clone 5 has recently been selected within TEG...
Background γ9δ2 T cells hold great promise as cancer therapeutics because of their unique capability reacting to metabolic changes with tumor cells. However, it has proven very difficult translate this into clinical success. Methods In order better utilize the reactivity γ9δ2T and combine potential cell engager molecules, we developed a novel bispecific molecule by linking extracellular domains tumor-reactive γ9δ2TCRs CD3-binding moiety, creating gamma delta TCR anti-CD3 molecules (GABs)....
Key Points We describe a novel allo-tumor–reactive and CD8α-dependent Vγ5Vδ1TCR. The molecular interface with proximity to the peptide-binding groove of HLA-A*24:02 is an essential determinant recognition.
Following successes of authorized chimeric antigen receptor T-cell products being commercially marketed in the United States and European Union, product development T-cell-based cancer immunotherapy consisting cell-based advanced therapy medicinal (ATMPs) has gained further momentum.Due to their complex characteristics, pharmacological properties living cell are, contrast classical biological drugs such as small molecules, more difficult define.Despite availability many new technologies that...
ABSTRACT Vγ9Vδ2T cells have the unique ability to recognize a broad range of malignant transformed cells. The tumor targeting event involving BTN2A1 and BTN3A1 dimers on cell surface is critical, leading full activation TCR. Although molecular mechanisms governing TCR engagement T are well-characterized, role Vγ9Vδ2 in cancer immune surveillance remains be fully elucidated, particularly that enable these discriminate between healthy at an early stage transformation. We employed two...
Abstract γδT cells play an important role in cancer immunosurveillance and are able to distinguish malignant from their healthy counterparts via γδTCR. This characteristic makes attractive candidate for therapeutic application immunotherapy. Previously, we have identified a novel CD8α-dependent tumor-specific allo-HLA-A*24:02-restricted Vγ5Vδ1TCR with potential value when used engineer αβT HLA-A*24:02 harboring individuals. engineered express this defined (TEG011) been suggested recognize...
With the development of this work, we seek to highlight importance implementing technological tools in study subject material resistance, order accompany teaching-learning process. Bringing computational on par with traditional learning classroom by applying a series innovative alternatives and work practices, outside that meet your expectations progress fields related resistance materials , who are under their responsibility aligned objective advancing career practical knowledge. This...
Summary Cellular immunotherapies are rapidly gaining clinical importance, yet predictive platforms for modeling their mode of action lacking. Here, we developed a dynamic immuno-organoid 3D imaging-transcriptomics platform; BEHAV3D, to unravel the behavioral and underlying molecular mechanisms solid tumor targeting. Applied an emerging cancer metabolome-sensing immunotherapy: TEGs, first demonstrate targeting multiple breast subtypes. Live-tracking over 120,000 TEGs revealed diverse...
γδT cell receptors (γδTCRs) recognize a broad range of malignantly transformed cells in mainly major histocompatibility complex (MHC)-independent manner, making them valuable additions to the engineered immune effector therapy that currently focuses primarily on αβTCRs and chimeric antigen (CARs). As an exception rule, we have previously identified γδTCR, which exerts antitumor reactivity against HLA-A*24:02-expressing malignant cells, however without need for defined HLA-restricted...
Quorum sensing is known as a communication mechanism among bacteria to control gene expression such bioluminescence, pigmentation, and pathogenicity. quenching inhibition of quorum activity. In order block activity, some produced enzymes which could degrade AHL, AHL-acylase, AHL-lactonase, AHL-oxidase reductase. this study, soil were isolated screened for their These isolates divided into Streptomyces non-Streptomyces isolates. Detection done by using Chromobacterium violaceum an indicator...
Abstract γδT cells mediate cancer immune surveillance by sensing metabolic changes of malignant via their cell receptor (TCR). Activation γδTCR is independent MHC molecules, making them a valuable addition to current treatment strategies. Moreover, are able differentiate between healthy and leukemic stem cells. This concept led the development next generation CAR T cells, so-called TEGs: αβT Engineered express defined γδTCR. A particular γ9δ2TCR, isolated from “clone 5”, has been selected as...
Abstract Despite the ability of γδT cells to mediate tumor killing independently MHC recognition, all clinical trials that have been carried out using these showed low response rate in patients, part due its poor proliferation ability. Recently, a new generation CAR-T called αβT engineered express defined γδTCR (TEG) has developed. TEGs are γδTCR. These able effective antitumor reactivity without showing any towards healthy tissue, and combine best qualities both cells. In fact, high...